# A Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Non-Erosive Reflux Disease

> **NCT05587322** · PHASE3 · COMPLETED · sponsor: **Braintree Laboratories** · enrollment: 800 (actual)

## Conditions studied

- Non-erosive Reflux Disease

## Interventions

- **DRUG:** BLI5100
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05587322
- **Lead sponsor:** Braintree Laboratories
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-06
- **Primary completion:** 2023-10-13
- **Final completion:** 2024-04-23
- **Target enrollment:** 800 (ACTUAL)
- **Last updated:** 2024-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05587322

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05587322, "A Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Non-Erosive Reflux Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05587322. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*